logo
episode-header-image
Mar 2024
58m 12s

The Scientific Journey Behind Ozempic (w...

Ben Gilbert And David Rosenthal
About this episode

On our Novo Nordisk episode, we covered the business of Ozempic, the GLP-1 taking the world by storm. On this episode, we dive into the science of the molecule semaglutide (and its predecessor liraglutide) with the world expert on the topic, Lotte Bjerre Knudsen. Lotte is Novo Nordisk’s Chief Scientific Advisor, and led the research group back in the early 1990s that first invented the molecule. A few topics from our conversation:

  • The science behind what is happening in the body that causes weight loss while on Ozempic
  • What it was like in the 1990s and 2000s believing in a drug for a problem that the rest of the industry (including her own company) had written off
  • How weight loss was actually a goal from the very start — not just a side effect of diabetes medication like you often read today!

Sponsors:


Up next
Dec 2025
The Insane Productivity of Andrew Ross Sorkin
Andrew Ross Sorkin does the work of about five people. He founded and writes the DealBook newsletter for the New York Times. He hosts Squawk Box on CNBC every morning at 6am. He runs the DealBook Summit, which has become the premier annual interview event across business, policy, ... Show More
1h 14m
Sep 2025
How to Live in Everyone Else's Future (with Shopify CEO Tobi Lütke)
Tobi is one of the most thoughtful people in the technology industry. He's also one of the very few people who started as a programmer -- just trying to solve his own problem -- and still runs his company as CEO today even as it approaches a $200B market cap. Tobi has done this i ... Show More
1h 47m
Aug 2025
How is AI Different Than Other Technology Waves? (With Bret Taylor and Clay Bavor)
Is AI just better software? Or something completely different that requires a new paradigm to understand? Today we sit down with Bret Taylor and Clay Bavor, two of the best product builders in the world to tackle that question. Bret and Clay are the co-founders of the AI company ... Show More
1h 13m
Recommended Episodes
Jun 2025
Lotte Bjerre Knudsen: Shivering with Curiosity
<p>Ozempic is one of the most important new medications in a generation. The driving force behind it is the Danish pharmaceutical company Novo Nordisk, which has been invested in GLP-1 research since the early 1990s. The leading scientist in this domain, a self-described "nerd," ... Show More
59m 20s
Jun 2024
Introducing The Journal: Trillion Dollar Shot
Today we’re presenting Trillion Dollar Shot, a new series that explores the business story behind the rise of Ozempic and other blockbuster drugs being used for weight loss. The first episode focuses on the Novo Nordisk scientist who invented the compound that paved the way for O ... Show More
41m 6s
Dec 2024
068 | The weight is over: How GLP-1 treatments are reshaping pharma and beyond
Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ... Show More
11m 16s
Jun 2024
The weight-loss drug revolution
Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of ... Show More
17m 28s
Jan 2024
Novo Nordisk (Ozempic)
Last year Novo Nordisk, the Danish pharmaceutical company behind Ozempic and Wegovy, overtook LVMH to become Europe’s most valuable company. And the pull for Acquired to finally tackle healthcare (18% of US GDP!) became too strong for us to resist. While we didn’t know much about ... Show More
3h 35m
Oct 2023
Semaglutide: Decoding the hype around the weight loss wonder drug
<p>From Elon Musk to several Hollywood celebrities, the weight loss wonder drug, semaglutide, is taking the world by storm. What was an unintended consequence of a diabetes control med, the emergence of significant weight loss has raised the expectation of the wonder drug becomin ... Show More
32m 7s
Mar 2025
The State of Weight-Loss Drugs
$150 billion. That’s how much some experts estimate weight-loss drugs could bring in in sales within the next five years. Motley Fool analyst Karl Thiel joins Ricky Mulvey to check in on the GLP-1 landscape. They also discuss: - How weight-loss drugs actually work, and how big- ... Show More
30m 7s
Dec 2024
Deep Dive: The Gold Rush to Cure the Obesity Epidemic
<p>GLP-1 weight-loss drugs, such as Novo Nordisk's Ozempic and Eli Lilly's Zepbound, are credited with reversing obesity trends in the U.S. for the first time in decades, according to a new study in the Journal of the American Medical Association. The episode highlights the rapid ... Show More
8m 47s
Feb 2024
The Ozempic economy
The weight loss drug is so profitable that its parent company, Danish health care giant Novo Nordisk, is propping up Denmark’s entire economy. It’s poised to transform America’s too. This episode was produced by Victoria Chamberlin edited by Jolie Myers, fact-checked by Kim Eggle ... Show More
25m 53s